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Two studies involved moderately emetogenic regimens. Pal-
onosetron 0.25mg was associated with a signiﬁcantly higher
complete response (CR) rate in the delayed phase compared to
ondansetron (74.1% vs. 55.1%, p = 0.001) and dolasetron
(54.0% vs. 38.7%, p = 0.004). The CR rate with palonosetron
0.25mg in the acute phase was signiﬁcantly higher than
ondansetron (81.0% vs. 68.6%, p = 0.009), but only numeri-
cally better than dolasetron (63.0% vs. 52.9%, p = 0.049). In
the trial with highly emetogenic agents, CR rates were compa-
rable between palonosetron 0.25 mg and ondansetron in both
the acute (59.2% vs. 57.0%, p = 0.701) and delayed (45.3%
vs. 38.9%, p = 0.180) phases. The FDA considered the CINV
claims relative to placebo due to lack of approval of compara-
tors for delayed CINV. Because of its long half-life, NCCN
guidelines indicated that single-dose palonosetron could be con-
sidered at the start of a multi-day chemotherapy regimen
instead of multiple daily doses of other 5-HT3-RAs; however,
none of the guidelines designated a preferred 5-HT3-RA. CON-
CLUSION: 5-HT3-RAs can be considered clinically inter-
changeable. While palonosetron may provide convenience by
avoiding the need for repeat daily dosing, this needs to be bal-
anced against its additional cost given the advent of generic
5-HT3-RAs.
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OBJECTIVE: Multiple myeloma (MM) is a plasma-cell malig-
nancy with approximately three years median survival. Patients
usually relapse or become refractory to existing treatments. Bort-
ezomib(VELCADE) is indicated for the treatment of MM in
patients who have received at least one prior therapy. The elec-
tronic VELCADE Observational Study (eVOBS) is a multicenter
naturalistic study designed to evaluate the clinical and outcomes
beneﬁts of bortezomib in actual clinical practice. METHODS:
This is a multi-center study with sites in Belgium, France, Greece,
Russia, Spain, Sweden, and Turkey. The study enrollment period
is between October 2006 and December 2008 with a 3-year
follow-up. Adults are eligible for study if they are scheduled to
initiate bortezomib within the approved indication. All bort-
ezomib dosages and concomitant treatments are permitted,
except investigational therapies. Data treatment response, and
safety are collected prospectively. RESULTS: The current analysis
reports data collected on patients initiated with bortezomib
between October 2006 and July 2007. A total of 86 pts with at
least four months of data are included in this analysis. Demo-
graphic and clinical characteristics of the initial participants were
similar to those of the participants in the prospective controlled
phase 3 APEX trial. Adverse events (AEs) were reported in 61
(71%) pts, including Grade 3 AEs in 38% and Grade 4 AEs
in 9%. AEs were treatment-related in 45% of patients and
treatment-limiting in 9%. Presently, 72 of 86 pts have been
evaluated for response, of whom 5 (7%) achieved complete
response, 9 (13%) achieved near complete response, and 30
(42%) achieved partial response. Updated data will be presented
at the meeting. CONCLUSION: In this preliminary analysis of
data from a prospective, observational study, response rates and
safety data demonstrate that bortezomib-containing regimens are
effective and well-tolerated in the treatment of MM in actual
clinical practice and the results are in line with previously pub-
lished studies.
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OBJECTIVES: The Nationwide Inpatient Sample is part of the
Healthcare Cost and Utilization Project, and is the only national
hospital database with charge information on all patients,
regardless of payer, including persons covered by Medicare,
Medicaid, private insurance, and the uninsured. It is the purpose
of this study to examine the relationship between patient out-
comes and conditions of the patients undergoing different treat-
ments for lung cancer. METHODS: There are ﬁfteen possible
patient diagnoses in the dataset. SAS Enterprise Guide was used
to obtain Lung Cancer data from NIS by using the CATX and the
RXMATCH statements in SAS. We bring all ﬁfteen diagnoses
into one column as a string of codes, using the CATX function.
Total charges are used to examine the relationship between diag-
noses and procedures. The generalized linear regression model
was used to ﬁt the data. RESULTS: After ﬁltering down to lung
cancer using the strings of diagnoses, there were 5457 records in
the data set. By the plot method, we selected variables related to
Total charges. We found that the Total charges were highly
related to Age in years at admission, Diagnosis Related Group,
Length of stay and Died during hospitalization. By the basic
criterion, deviance residuals and Pearson chi-square residuals,
the speciﬁed model ﬁts the data reasonably well. From the Type
1 and Type 3 analysis, all the estimates for the intercept, Los,
Age, DRG, and Died were 10.1805, 0.1181, 0.003, -0.0008, and
-1.024, respectively. All of them were statistically signiﬁcant.
Co-morbid diagnoses that increased total charges include coro-
naries, multiple signiﬁcant traumas, and cardiac implant. CON-
CLUSIONS: Our analysis revealed that there was a speciﬁed
relationship between these variables. With increasing of length of
stay, age in years at admission, small codes of diagnosis related
group and surviving during hospitalization, the total charges
increase, which is reasonable.
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OBJECTIVE: Complications from skeletal-related events (SREs)
constitute a challenge to the care of patients with bone metastasis
originated from any type of malignancy. Our objective was to
determine the reduction in morbidity (SREs) and mortality
(overall) of clodronate, pamidronate, and zoledronic acid in
patients diagnosed with bone metastasis. METHODS: Medline
and Embase (from inception to October 2007) were searched in
order to retrieve randomized clinical trials evaluating targeted
bisphosphonates in cancer patients with bone metastasis.
Patients with a deﬁnite (i.e., biopsy-proven) diagnosis of meta-
static bone disease were included in the analysis. We extracted
and combined data from studies describing the number of
patients reporting 12-month SREs and mortality data. Two inde-
pendent reviewers identiﬁed articles, then extracted data; results
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were compared and settled through consensus. A random-effects
meta-analytic model was applied in all calculations. Jadad’s scale
assessed study quality of reporting. RESULTS: A total of 50
potential studies were identiﬁed. Thirty-ﬁve were excluded and
15 were evaluated. Quality of reporting of included studies was
on average 59  24%. All three drugs showed beneﬁcial effects
in preventing all SREs over placebo in cancer patients with
bone metastasis. Zoledronate was the pharmacological strategy
reporting the lowest relative risk (RR = 0.67; CI95% = 0.55,
0.81; N = 695), followed by pamidronate (RR = 0.79;
CI95% = 0.71, 0.88, N = 1951), and clodronate (RR = 0.87;
CI95% = 0.75, 1.00; N = 681). However, no clear advantage of
one drug over the others was observed since conﬁdence intervals
overlapped substantially. All targeted bisphosphonates showed
no beneﬁts over placebo in reducing the number of deaths in a
12-month period (p > 0.05). CONCLUSION: Clodronate, pam-
idronate, and zoledronate are able to reduce the morbidity of
patients with bone metastasis in regards to SREs but not overall
mortality.
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OBJECTIVE: To assess the potential value of trastuzumab (T) to
society, we initially assessed the long-term impact of T treatment
in early breast cancer (EBC) on the annual number of patients
developing metastatic BC (MBC) from 2005–2015 in ﬁve Euro-
pean countries. METHODS: Annual EBC incidence for 2003–
2015 was projected by applying stage-speciﬁc proportions for
stages I-III, according to regional registry data, to published
female BC incidence rates from 1990–2002. Age-speciﬁc rates for
2002 were then applied to United Nations 2003–2015 popula-
tion projections. The annual number of patients with HER2-
positive MBC includes de novo MBC incidence plus patients with
BC recurrence. The baseline 10-year recurrence rate for standard
treatment was estimated as 37%, based on 4-year follow-up in
the control arm of a combined trial analysis in patients with
HER2-positive BC and the long-term timing of recurrence in all
patients with BC. To model recurrence in T-treated EBC patients,
the hazard ratio at median 1-year follow-up in the HERA trial
(0.49; 95% conﬁdence interval [CI]: 0.38, 0.63) was applied,
resulting in an estimated 10-year recurrence rate of 18.1% (95%
CI: 14.0, 23.3). RESULTS: In 2004, prior to T approval for EBC,
the pool of de novo and relapsed MBC patients was estimated at
16,156. Between 2005 and 2015, the model predicts that T
treatment will result in an annual decline of 2.5% (95% CI: 1.7,
3.2). The total number of patients prevented from developing
metastases over 10 years is projected to be 27,727 (95% CI:
20,116, 33,709). CONCLUSION: T is expected to prevent
nearly 28,000 women from developing MBC over a 10-year
period in ﬁve countries alone and should considerably reduce the
health resource burden of MBC treatment.
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OBJECTIVE: Surgery is main treatment used in most early breast
cancer cases; surgery is the primary treatment for breast cancer to
remove as many as cancer cells as possible. There are two types
of surgeries: mastectomy and lumpectomy. Studies have shown
that mastectomy is the most performed in comparison to lumpec-
tomy. With our data, out of 1485 cases of breast cancer, 146 were
primarily treated by mastectomy while only 26 were treated with
lumpectomy. We analyzed, in detail, the information on mastec-
tomy as a treatment option for breast cancer to compare the use
of different types of mastectomy and to study the cost of the most
frequent types. METHODS: We used the 2004 data from the
National Inpatient Sample (NIS). We ﬁrst ﬁltered the data with
respect to the main types of mastectomy: radical mastectomy,
modiﬁed radical mastectomy, simple (total) mastectomy, and the
subcutaneous mastectomy. Second, we analyzed them with
summary statistics using SAS, and then ﬁnally, we looked at the
cost of the most frequent by plotting the actual costs and the
future trend. We used SAS Text Miner to compress patient diag-
noses, and compare them to the types of treatment. RESULTS:
The modiﬁed radical mastectomy is the most frequently used in
treating breast cancer with 81.5% of the total mastectomies.
Then, we have the simple (total) mastectomy with 13.7%.
Finally, we have the subcutaneous mastectomy (2.7%) and the
radical mastectomy (2.1%). The cost of the modiﬁed radical
mastectomy has a constant trend of around $20,000. CONCLU-
SION: The modiﬁed radical mastectomy is the most performed
so far in the treatment of breast cancer by mastectomy. SAS can
be used to study health care cases.
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OBJECTIVE: Glioblastoma multiforme (GBM) accounts for
35% of primary brain tumor in Taiwan. The objective of this
study is to determine if patients with GBM survived longer after
adjuvant therapy by temozolomide. METHODS: We collected all
inpatients of GBM veriﬁed with pathology in Chang Gung
Memorial Hospital from January 2001 to March 2006. Patients
aged more than 80 at diagnosis were excluded. Outcome was
followed until December 31, 2006. Survival analysis was per-
formed by Kaplan-Meier estimation method and Cox regression
model and explores the effect related to various prognostic
factors including adjuvant therapy of temozolomide. RESULTS:
There were 66 temozolomide users and 133 non-users during the
study period. They were no statistical signiﬁcant differences on
gender, age at diagnosis and year of diagnosis between these two
groups. Analysis showed 50% survival for users and non-users
were 18.7 and 9.9 months, respectively (Log-rank test,
p < 0.0001). The hazard ratio was 2.58 (95% conﬁdence inter-
val, 1.60–4.16) for the aged 60–80 compared with patients aged
20–40, and that of temozolomide treatment was 0.47 (.34–.66).
Stratiﬁed analysis showed that there was no signiﬁcant difference
in survival between patients with concomitant radiotherapy.
CONCLUSION: The adjuvant therapy with temozolomide
seemed to improve survival, but randomized trial is still needed
to test this hypothesis.
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